GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial

被引：0
|
作者：
Cryer, Byron [1 ]
Li, Chunming [2 ]
Simon, Lee S. [3 ]
Singh, Gurkirpal [4 ]
Stillman, Martin J. [5 ]
Berger, Manuela [2 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Pfizer Inc, New York, NY USA
[3] SDG LLC, Cambridge, MA USA
[4] Stanford Univ, Palo Alto, CA 94304 USA
[5] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
来源：
ARTHRITIS RESEARCH & THERAPY | 2012年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P63
引用
收藏
页数：1
相关论文
共 50 条
  • [1] GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded End Point (PROBE) Trial
    Cryer, Byron
    Li, Chunming
    Simon, Lee S.
    Singh, Gurkirpal
    Stillman, Martin
    Berger, Manuela
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S777 - S778
  • [2] GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded End Point (PROBE) Trial
    Cryer, Byron
    Li, Chunming
    Simon, Lee
    Singh, Gurkirpal
    Stillman, Martin
    Berger, Manuela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S85 - S85
  • [3] GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded end point (PROBE) trial
    Byron Cryer
    Chunming Li
    Lee S Simon
    Gurkirpal Singh
    Martin J Stillman
    Manuela Berger
    Arthritis Research & Therapy, 14 (Suppl 1):
  • [4] GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
    Cryer, Byron
    Li, Chunming
    Simon, Lee S.
    Singh, Gurkirpal
    Stillman, Martin J.
    Berger, Manuela F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (03): : 392 - 400
  • [5] A 6-month open-label trial of tolcapone in Parkinson's disease
    Charles, PD
    Davis, TL
    SaintHilaire, MH
    Trosch, RM
    LeWitt, P
    Kurth, MC
    Pedder, S
    Dorflinger, E
    ANNALS OF NEUROLOGY, 1997, 42 (03) : M64 - M64
  • [6] Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open-label, blinded-end-point trial
    Oh, Mi Sun
    Yu, Kyung-Ho
    Hong, Keun-Sik
    Kang, Dong-Wha
    Park, Jong-Moo
    Bae, Hee-Joon
    Koo, Jaseong
    Lee, Juneyoung
    Lee, Byung-Chul
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (05) : 745 - 751
  • [7] Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial
    Wei, JCC
    Chan, TW
    Lin, HS
    Huang, F
    Chou, CT
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (12) : 2627 - 2631
  • [8] Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design
    Kohro, Takahide
    Yamazaki, Tsutomu
    HYPERTENSION RESEARCH, 2009, 32 (02) : 109 - 114
  • [9] Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design
    Takahide Kohro
    Tsutomu Yamazaki
    Hypertension Research, 2009, 32 : 109 - 114
  • [10] Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open-label, randomized trial
    Szefler, SJ
    Warner, J
    Staab, D
    Wahn, U
    Le Bourgeois, M
    van Essen-Zandvliet, EEM
    Arora, S
    Pedersen, S
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 110 (01) : 45 - 50
12345